Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings

Some patients with nonalcoholic steatohepatitis have relatively low leptin levelsIn this subgroup, leptin therapy leads to reduced hepatic fat and lower NASH scoresSimilar improvements are observed in a group of subjects with partial lipodystrophyThe therapeutic benefit of leptin may go beyond severe leptin deficiency